Introduction
Human Immunodeficiency virus, HIV-1 initiates infection via viral envelope (Env) glycoprotein gp120 interacting with cell surface CD4, followed by its association with a co-receptor that triggers the fusion of viral and host-cell membranes. Two chemokine receptors, CCR5 and CXCR4 are the predominantly known co-receptors for HIV-1 in vivo. All HIV-1 strains are classified phenotypically as R5 (Macrophage tropic), X4 (T-cell tropic), or R5X4 (dual tropic i.e. both M-tropic and T-tropic) depending on whether they preferentially utilize cysteinecysteine receptor 5 (CCR5) or cysteine-X-cysteine receptor 4 (CXCR4) or mixed [1] . This inter-conversion of tropism requires only a small number of changes in the Env V3 region. In early stage of HIV infection, only about 15% are dual/mixed tropic and is dominated by CCR5 tropism [2, 3] . While in later stages of the disease, dual/mixed or pure CXCR4 tropism reaches up to 60% [4] , and is highest in patients with CD4 ≤ 200 cells/μl [5, 6] .This may vary with the prevalence of HIV-1 subtype in a region. Why there is selective advantage of CCR5 tropic viruses in establishing HIV-1 infection, switching over to CXCR4 utilization in the advanced stage of disease, is not clearly understood yet. This tropism switch has been associated with rapid disease progression and poor clinical prognosis [7] [8] [9] . Besides preferential CXCR4-utilizing virus, there may be other factors also playing crucial role in faster disease progression and needs a closer look. It has earlier been indicated that Rac1,a small (~21 kDa) signaling G protein a member of the Rac subfamily of the Rho family of GTPases, is important to maintain the functional conformation of CXCR4 receptor [10] , and could be one of the candidate molecules that could possibly play an important role in preferential co-receptor utilization by the virus.
Normal cell functioning of host is altered by invading viral proteins to the benefit of the virus [11] . There have been constant efforts to understand these interactions between viral and cellular gene products which together determine the host's susceptibility to infection and disease progression in HIV-1 infection [12] . In order to have a subtype C specific prediction model, a three dimensional structure of local wild type C variant is created and the identified mutations were introduced to assess the mutational effects on protease inhibitors (PI) in a homology model. We estimated viral load, CD4 count and conducted DR genotyping in HIV isolates from 129 therapy naive and 20 first-line treatment failure individuals. Several genotypic variations, as compared to subtype B sequence in the Stanford gene database were detected in HIV-1 subtype C isolates from treatment naive individuals. Among these, nine mutations (12S, 15V, 19I, 36I, 41K, 63P, 69K, 89M, 93L) occurred in more than 60% of the isolates and were considered as local wild type for molecular modelling studies. No major mutations were seen in the PR sequences in isolates from treatment-naive individuals, although isolates from two patients had T74S mutation, known to be associated with reduced susceptibility to nelfinavir (NFV) and a combination of M36I, H69K and L89M mutations found in isolates from 77 patients (59.7%), considered to be conferring resistance to tipranavir (TPV) according to ANRS algorithm. Among the first-line treatment failures, an isolate from one patient showed L33F, I47T, M46G, and G48E mutations conferring intermediate resistance to saquinavir (SQV) and lopinavir (LPV). Though the docking energy scores are in agreement with this interpretation for SQV, it, however, indicated these mutations to be causing intermediate to high level resistance to atazanavir (ATV) and tipranavir (TPV) but making it susceptible to LPV. The patient finally responded to a second-line regimen containing 3TC, AZT and LPV with significant viral suppression.
All the DR genotyping studies analyse the results using available databases which are all based on subtype B specific sequences. The proposed homology model in this study is unique, as it may predict subtype C specific susceptibility criteria for the available PIs.
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Drug resistance (DR) is inevitable consequence of incomplete suppression of Human Immunodeficiency virus (HIV) replication. The rapid turnover of HIV-1 RNA and its genetic variability leads to the production of many variants with decreased drug susceptibility (Ho et al., 1995; Perrin and Telenti, 1998) . With the emergence of failure to first-line treatment consisting a combination of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and NonNucleoside Reverse Transcriptase Inhibitors (NNRTIs) in India, National AIDS Control Organisation (Government of India) introduced second-line treatment in 2009 which includes one protease inhibitor (PI) and two NRTIs in triple drug combination therapy.
Protease inhibitors (PIs), originally designed and tested against the subtype B viruses are currently also made available in other parts of the world including Indian subcontinent where the epidemic is dominated by subtype C (Arora et al., 2008; Deshpande et al., 2004; Sen et al., 2007) . Importantly, the Stanford DR mutation database is mainly subtype B sequence based, and some reports including data (unpublished) from our own laboratory have indicated that protease (PR) gene in subtype C displays a reasonable level of sequence variability from subtype B and so rise the question of whether the DR mutations mentioned in the Stanford database will behave in a similar fashion for subtype C PR as well (Kinomoto et al., 2005) 
Acquired Immunodeficiency Syndrome (AIDS), caused by the human immunodeficiency virus (HIV), is one of the leading causes of death with major medical and economic impact on the society. Due to high mutation rates associated with RNA replication and retrotranscription, there is spontaneous emergence of a pool of mutant viruses, some of which may be associated with drug resistance (DR) [1] [2] [3] . Keeping in mind the increasing demand of improving the drug efficacy, there is an urge to improve the methodology of identification of these mutations and know how they affect the susceptibility to a particular drug.
Subtype C of the HIV-1 is accountable for over 50% of the HIV-1 infections in Southeast Asia and African Countries while subtype B predominates in Western Europe and North America [4] [5] [6] [7] . An increasing body of experimental evidence suggests that different HIV-1 subtypes exhibit disparate biological behaviors, and might respond differently to diagnostic, immunologic and therapeutic interventions [8, 9] . Recent studies have identified subtype specific differences in HIV susceptibility to specific anti-retroviral drugs [10, 11] and signature mutations selected by treatment [12] [13] [14] . An increased amount of resistance in subtype C HIV has been documented as compared to other subtypes in response to single-dose NVP therapy [15, 16] . This indicates that subtype of HIV might have influence on the level of resistance development against a particular anti-retroviral drug under that drug pressure and deserves further attention to prove this fact. For genotypic analysis of isolates from infected individuals the sequences need to be analyzed using one of the few drug-resistance databases available which include Stanford DR database, the Los Alamos HIV sequence database, the Rega algorithm for HIV subtype analysis, International AIDS society drug-resistance information to name a few. All these databases are mainly based on subtype-B sequences. In order to have a better The intrapatient viral population is a highly dynamic system, characterized by short replication cycles and high turnover rates. Since viral replication is highly error prone due to the lack of proofreading capacity of the viral RT, these dynamics can quickly generate resistant variants that have a selective advantage during drug pressure.
The management of persons who develop drug resistance or who are infected primarily with a drug resistance virus remains a clinical challenge. Hence, resistance testing has become an important diagnostic tool in the management of HIV infection. Resistance assays are either based on analyzing the viral genome to identify resistance-associated mutations (genotypic resistance testing) or on direct in vitro measures of drug susceptibility (phenotypic resistance testing). [4] [5] [6] Genotypic assays for drug resistance determine the nucleotide sequence of the HIV genome allowing the detection of resistance-associated mutations that may precede a shift in the phenotypic susceptibility affecting the long-term efficacy of antiretroviral therapy (ART). The primary goal of HIV-1 antiretroviral genotyping is to extend the maximal viral suppression for the longest time period, ideally to prevent HIV progression and AIDS complications in treated patients. 7 Since the detection of the first HIV case in Chennai in 1986, India has come close to having an AIDS epidemic. 8 The estimate of 5.7 million HIV-infected people in India, as compared to 5.5 million people in South Africa, captured wide attention. Though the ready availability of generic antiretroviral (ARV) Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
